BIOLEAP will be speaking at the Spacewalk VC & Motius Conference on April 25th in Munich, Germany. We will be sharing more about the importance of shifting from drug discovery to drug engineering - How biophysics and AI are changing the development of next generation medicines". Tickets can be requested using the link below. https://lnkd.in/d4amuaxq
Bioleap
Biotechnology Research
Enabling the development of next generation biologics in-silico using physics-first biophysical models + AI
About us
We're a Pharmatech company, leveraging a systems-modelling approach to develop the next generation of biologics. By leveraging a combination of AI and Physics, we've solved one of the key challenges of building large complex biophysical models. This presents us with a paradigm shift in our ability to take a rational approach to finding the optimal modalities of therapeutics to take forward into development, as we can infer previously unknown properties about these therapies and simulate all possible options to find the most efficacious, whilst retaining full mechanistic understanding of how and why they work. The 85-90% attrition rate at clinical trial for immuno-oncology therapies, which costs pharma $50billion+ year in failed trials, has been attributed to the lack of quality predictive pre-clinical models. We believe that a systems-based approach to in-silico modelling is the clear-cut solution to this problem. Our patent-pending technology reduces parameter uncertainty by up to 100x compared with existing biophysical or AI approaches, reducing data requirements by 10-20x. This is an order of magnitude shift, unlocking new possibilities for in-silico modelling of large-scale complex disease systems. This patent-pending innovation is at the core of Bioleap's mission. Our culture is one of open-ness. To challenge, to innovation, to research. Collaboration, breaking barriers, removing silos - with rigorous scientific intention and creative endeavour. We're taking on the greatest challenges facing biology. For that we're going to need the brightest minds - creating an ecosystem that provides the necessary environment to solve problems that have never been solved before.
- Website
-
https://bioleap.ai
External link for Bioleap
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Cambridge
- Type
- Privately Held
- Founded
- 2022
Locations
-
Primary
Get directions
Station Road
Cambridge, GB
Employees at Bioleap
Updates
-
The BIOLEAP team will be at Deep Tech Momentum 2024 in Berlin. We look forward to seeing many of the great people we’ve been speaking to over the last 12 months! https://lnkd.in/e-ftEEnV
Deep Tech Momentum 2024
deeptech.build
-
Great to be part of the 2024 Cancer Tech Accelerator Programme with Capital Enterprise. Excited to be part of another great cohort that are pushing the boundaries in oncology with some great partners onboard, including Cancer Research UK (CRUK), Roche, LifeArc and more. https://lnkd.in/dY_SvhW
-
-
Dr Jacob Halatek, Founder and CTO at BIOLEAP, will be presenting at the international workshop on the Physics of Biological Cells: From molecules to populations. The conference will be at the Higgs Centre for Theoretical Physics, University of Edinburgh in May. https://lnkd.in/eZAExiBs
Workshop: Physics of Biological Cells: from molecules to populations - Higgs Centre for Theoretical Physics
higgs.ph.ed.ac.uk
-
Great to see progression in the application of CAR-T for MS. https://lnkd.in/dNEhYt4t
CAR-T therapy for multiple sclerosis enters US trials for first time
nature.com
-
It was great to be part of the 2023 P4 Precision Medicine Accelerator Cohort. Big thank you to Lotus Qi, Nathan McNally and the rest of the Capital Enterprise team for helping to accelerate early-stage startups in the UK.
-
We are very excited to have made it into the final round for Most Promising European Deep tech in 2023 and we look forward to presenting on the day! Big thank you to the judges, Frontier Deep Tech, Silicon Roundabout Ventures and the 50+ top tier VCs supporting this event. We live in a world where a 90% failure rate in drug development is considered a success. This is simply not sustainable. And it is not necessary. Our mission is clear - applying physics-driven engineering principles to drug development allows us to integrate our siloed understanding of biological systems and radically shift our approach from drug discovery to drug engineering through model-driven-design, finding the optimal therapeutics to invest in and develop.
-
-
Immuno-oncology therapies have shown great promise in the fight against cancer, but they are incredibly complex, leading to a high degree of uncertainty during development and a 90% failure rate during clinical trial. We're on a mission to solve these problems, enabling Pharma to design and develop effective immunotherapies for cancer by analysing the effects these therapies have on disease in-silico; guiding future development through rigorous predictions and recommendations for how therapies can be developed to improve efficacy and safety. Our patent-pending Hybrid technology leverages the strengths of mechanistic modelling and AI, to create a new paradigm in the development of true synthetic biology based therapeutics. Using this technology, enables Bioleap to solve the complexity problem of large scale models and has proven its effectiveness: > Requires 10 - 20x less data required to calibrate highly predictive models > Produces 35 - 100x better predictions compared to existing QSP mechanistic models or AI models > Embedded explainability layer that allows researchers to probe the mechanistic science behind their predictions